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The present study evaluated endogenous activities and the role of BMP and TGF-β, 
representative members of the TGF-β family, during myotube differentiation in C2C12 
cells. Smad phosphorylation at the C-terminal serines was monitored, since TGF-β 
family members signal via the phosphorylation of Smads in a ligand-dependent manner. 
Expression of phosphorylated Smad1/5/8, which is an indicator of BMP activity, was 
higher before differentiation, and rapidly decreased after differentiation stimulation. 
Differentiation-related changes were consistent with those in the expression of Ids, 
well-known BMP-responsive genes. Treatment with inhibitors of BMP type I receptors 
or noggin in C2C12 myoblasts down-regulated the expression of myogenic regulatory 
factors, such as Myf5 and MyoD, leading to impaired myotube formation. Addition of 
BMP-2 during the myoblast phase also inhibited myotube differentiation through the 
down-regulation of Myf5 and MyoD. In contrast to endogenous BMP activity, the 
phosphorylation of Smad2, a TGF-β-responsive Smad, was higher 8 to 16 days after 
differentiation stimulation. A-83-01, an inhibitor of TGF-β type I receptor, increased the 
expression of Myf5 and MyoD, and enhanced myotube formation. The present results 
reveal that endogenous activities of the TGF-β family are changed during myogenesis 
in a pathway-specific manner, and that the activities are required for myogenesis. 
 




Skeletal muscle formation consists of a complex set of differentiation steps: 
commitment of mesenchymal stem cells to myoblast lineage cells, progression of 
differentiation with the expression of muscle-cell-specific proteins, and fusion of 
myoblasts into multinucleated myotubes. Skeletal myogenic differentiation is 
principally governed by activities of the MyoD family that are basic helix-loop-helix 
(bHLH) transcription factors. The MyoD family is also known as myogenic regulatory 
factors (MRFs), i.e., MyoD, Myf5, myogenin and MRF4. MRFs form a complex with E 
proteins, another class of bHLH transcription factors, such as E12 and E47, and 
stimulate the transcription of skeletal muscle-specific genes through binding to E-box 
(CANNTG) in the regulatory region [Ludolph and Konieczny, 1995; Perry and 
Rudnicki, 2000; Lluis et al., 2006]. To accomplish appropriate myogenesis, activities of 
MRFs must be strictly regulated. 
 
Transforming growth factor-β (TGF-β) family members, i.e., TGF-βs, activins and bone 
morphogenetic proteins (BMPs), are pluripotent growth factors involved in diverse 
physiological processes, and also participate in myogenesis in a ligand-dependent 
manner [Derynck et al., 2008]. Exogenous administration of TGF-β and myostatin to 
the culture medium inhibited myogenesis through the down-regulation of MRF 
expression [Vaidya et al., 1989; Brennan et al., 1991; Langley et al., 2002]. Exogenous 
administration of BMPs also inhibited myogenic differentiation, but in a different 
fashion from TGF-β-induced inhibition of myogenesis; BMP-2 treatment induced the 
transdifferentiation of myoblasts to osteoblast lineage cells [Katagiri et al., 1994; Lee et 
al., 2000; Maeda et al., 2004]. These studies, however, examined the effects of ligand 
administered exogenously, and there is little information on the role of the endogenous 




Members of the TGF-β family elicit their activities through a complex formation 
consisting of ligand, type I and type II receptor serine/threonine kinases. Activation of 
the type I receptor through transphosphorylation by the type II receptor induces the 
phosphorylation of C-terminal serines of receptor-regulated (R)-Smad. R-Smad is 
categorized into two subclasses: BMP pathway-specific R-Smad (Smad1, 5 and 8), and 
activin/TGF-β pathway-specific R-Smad (Smad2 and 3) [Feng and Derynck, 2005; 
Massagué et al., 2005; Heldin, 2008]. Subsequently, phosphorylated R-Smad forms 
complexes with common Smad, Smad4, which accumulate in the nucleus where they 
participate in transcriptional regulation of target genes. Thus, serine phosphorylation of 
R-Smad at the C-terminus is a key event in TGF-β family signaling [Feng and Derynck, 
2005; Massagué et al., 2005; Heldin, 2008]. The objective of this study is to clarify the 
activities and roles of endogenous TGF-β family, especially BMPs and TGF-βs during 
myogenesis; the activities of the TGF-β family were monitored by the expression of 
phosphorylated R-Smad in a C2C12 myotube differentiation model. 
 
 
MATERIALS AND METHODS 
MATERIALS 
The following reagents were purchased: recombinant BMP-2 and recombinant noggin 
were from R&D Systems (Minneapolis, MN); dorsomorphin and A-83-01 were from 
Calbiochem; LDN-193189 was from Stemgent (San Diego, CA); rabbit polyclonal 
antibody against phospho-Smad1 (Ser463/Ser465) / Smad5 (Ser463/Ser465)/ Smad8 
(Ser426/Ser428) (#9511) and phospho-Smad2 (Ser465/Ser467) (#3101) were from Cell 
Signaling Technology; rabbit monoclonal antibody against Smad1 (ab33902), rabbit 
polyclonal antibody against Smad2 (ab63576), goat polyclonal antibody against Smad8 
(ab48011), mouse monoclonal antibody against MyoD (ab16148) and β-actin (AC-15) 
were from Abcam; rabbit polyclonal antibody against Myf5 (C-20) was from Santa 
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Cruz Biotechnology; mouse monoclonal antibody against myosin heavy chain (MyHC) 
(MY-32) was from Sigma; Alexa Fluoro 488 was from Invitrogen. 
 
CELL CULTURE 
C2C12 myoblasts were obtained from the American Type Culture Collection (Rockville, 
MD). Cells were cultured in growth medium, i.e., Dulbecco’s modified Eagle’s medium 
(DMEM) with heat-inactivated 10% fetal bovine serum (FBS), 100 U/ml penicillin and 
100 µg/ml streptomycin, at 37°C under a humidified 5% CO2 atmosphere. To induce 
differentiation from myoblasts to myotubes, the medium was replaced at confluence 
(day 0) with differentiation medium consisting of DMEM with 2% horse serum 
supplemented the antibiotics. To examine the effect of dorsomorphin and LDN-193189, 
BMP-specific inhibitors [Yu et al., 2008a, b], dorsomorphin at 4 µM, LDN-193189 at 
100 nM or an equivalent amount of vehicle (DMSO: 0.04%) was added to growth 
medium from day -2 to day 0. To evaluate the effect of endogenous BMP activity, 
noggin, a BMP antagonist [Yanagita, 2005], was also added at 2.5 or 25 ng/ml from day 
-2 to day 0. To examine the effect of A-83-01, an activin/TGF-β-specific inhibitor [Tojo 
et al., 2005], A-83-01 at 4 µM or the indicated concentrations, or an equal amount of 
vehicle (DMSO: 0.08%) was added to differentiation medium from day 8 to day 12 or 
the indicated period. 
 
WESTERN BLOTTING 
To examine time-course changes in Smad expression, cells were recovered in 200 mM 
phosphate buffer, pH 7.4, 2 M NaCl, 2 mM Na3VO4, 1 mM PMSF and 1% aprotinin, 
and lysed by ultrasonication. Protein concentrations were measured by the Lowry 
method, and an equal amount of protein was subjected to Western blot analyses as 
described previously [Funaba and Murakami, 2008; Suenaga et al., 2010]. After 
incubation of the membranes with ECL Plus reagent (GE Healthcare), the 
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chemiluminescent signals were captured and quantified by a LAS4000 mini 
biomolecular imager (Fuji Film, Tokyo, Japan). To examine the effects of the inhibitor 
or BMP-2, cells were lysed in 20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 
1% Triton X-100 with phosphatase and protease inhibitors. 
 
RT-PCR and qRT-PCR 
RNA isolation, RT-PCR and qRT-PCR were carried out as previously described 
[Furutani et al., 2009; Suenaga et al., 2010]. The following oligonucleotides were used 
as PCR primers: 5’-tgaaaacaccaggcgacata-3’ and 5’-tgaggcattccgcatacac-3’ for Smad1 
(Genbank accession number: NM_008539), 5’-gccactgtagaaatgacaagaaga-3’ and 
5’-cactatcacttaggcactcagca-3’ for Smad2 (NM_010754.4), 5’-cccagcacacaataacttgg-3’ 
and 5’-cgctggttcagctcgtagta-3’ for Smad3 (NM_016769.4), 
5’-gcagtaacatgattcctcagacc-3’ and 5’-gcgacaggctgaacatctct-3’ for Smad5 
(NM_008541.2), 5’-cggatgagctttgtgaagg-3’ and 5’-gggtgctcgtgacatcct-3’ for Smad8 
(NM_019483), 5'-tggccatgatcttgctgtaa-3' and 5'-ccttgacttctaaaaagggattca-3' for 
Myostatin (NM_010834.2), 5'-gaggacccacggaagtga-3' and 5'-cctcagctgttggcagtagg-3' for 
Gremlin1 (NM_011824.3), and 5'-agcactacagtggcgactca-3' and 5'-ggccgctgtaatccatcat-3' 
for MyoD (NM_010866.2). PCR primers of inhibitor of DNA binding (Id)s, TGF-β2, 
TGF-β3, Myf5, myosin heavy chain IIb (MyHC IIb), Hprt1, and Gapdh were previously 
described [Furutani et al., 2009; Murakami et al., 2009]. The relative mRNA level was 
expressed as a ratio with the Hprt1 mRNA level. 
 
IMMUNOFLUORESCENCE STAINING 
Cells cultured on glass coverslips were washed with phosphate-buffered saline (PBS), 
and fixed with 4% paraformaldehyde in PBS. The fixed cells were treated with 0.1% 
Triton X-100 in PBS for permeabilization, followed by blocking with Ez Block (Atto, 
Tokyo, Japan) in TBS-T (20 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% Tween 20) for 
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30 min. Cells were subsequently reacted with the primary antibody against MyHC in 
TBS-T for 1 h at 37°C. After washing with TBS-T, cells were incubated with Alexa 
Fluoro 488 and 1 µg/ml 4',6-diamidino-2-phenylindole (DAPI) in TBS-T for 1 h. The 
number of nuclei was calculated by Image J (http://rsbweb.nih.gov/ij/). Fusion index 
was calculated as a ratio of the number of nuclei incorporated in myotubes to the 




BMP ACTIVITY IS HIGHER BEFORE DIFFERENTIATION, WHEREAS TGF-β 
ACTIVITY IS HIGHER AFTER DIFFERENTIATION IN C2C12 CELLS 
To examine changes in endogenous BMP and activin/TGF-β activities during the 
differentiation of committed myoblasts, we first examined the phosphorylation of 
Smad1/5/8 and Smad2, respectively, by Western blot analyses using an antibody that 
recognizes the phosphorylation of C-terminal serines (Fig. 1A). When 
anti-phospho-Smad1/5/8 antibody was used, two bands were detected. Since the 
calculated molecular weight of Smad8 (48,420) is smaller than that of Smad1 (52,157) 
and Smad5 (52,172), the lower band may indicate phosphorylated Smad8. In fact, the 
lower band corresponded to the band detected by anti-Smad8 antibody (data not shown). 
The intensity of the lower band, i.e., phosphorylated Smad8, was higher before 
differentiation (Fig. 1A, lanes 1 and 2), and rapidly decreased after differentiation 
stimulation (Fig. 1A, lanes 3–7, Fig. 1B). By contrast, upper band intensity was 
relatively constant throughout the study. Since total Smad8 expression was also higher 
before differentiation (Fig. 1A, B), the ratio of phosphorylated Smad8 to total Smad8 
was relatively constant throughout the study (Fig. 1B).  
 
Western blot using anti-phosphorylated Smad2 antibody showed that a clear band was 
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detected on day 8 to 16 (Fig. 1A, lanes 5–7, Fig. 1C). The levels of total Smad2 were 
relatively lower but constant during myogenesis (Fig. 1A, C). Thus, the ratio of 
phosphorylated Smad2 to total Smad2 was higher on day 8 to 16 (Fig. 1C). 
 
Gene transcript levels of Smad1 and Smad5 were constant throughout the study; the 
expression levels varied within 40% of the level on day -2 (Fig. 1D and E). By contrast, 
the level of Smad8 mRNA was decreased after differentiation stimulation to 16% of the 
basal level on day -2 (Fig. 1F), which was consistent with that of Smad8 protein (Fig. 
1A). Variations of Smad2 and Smad3 expression were smaller during myogenesis, 
except for Smad3 expression on day 2 (Fig. 1G and H). 
 
Ids, proteins with an HLH domain lacking the basic domain [Norton, 2000], are 
transcriptionally activated in response to BMP-induced Smad activation [Korchynskyi 
and ten Dijke, 2002; Miyazono et al., 2005; Murakami et al., 2009]. Similar to changes 
in the phosphorylated Smad1/5/8 level, gene transcript levels of Id1, Id2 and Id3 during 
myogenesis were higher on day -2 to 0, and rapidly decreased in response to 
differentiation stimulation (Fig. 2). Taking these results with the phosphorylated Smad 
levels together, it is suggested that endogenous BMP activity is higher in 
undifferentiated C2C12 cells. 
 
To explore the possible molecules to induce endogenous BMP activity, we searched 
expression of BMPs and GDF family members, which induce Smad 1/5/8 
phosphorylation and activation, in a cDNA microarray database 
(http://www.ncbi.nlm.nih.gov/geo/) thoroughly. No BMPs and GDFs exhibited higher 
expression before differentiation stimulation (data not shown). BMP activity is 
negatively regulated by the presence of antagonists [Miyazono et al., 2010]. Thus, we 
also explored the known antagonists for the BMP pathway, of which the expression 
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level was higher after differentiation stimulation. Gene transcript level of Gremlin1 was 
increased after differentiation stimulation (Fig. 3A), but the extent of the increase in 
Gremlin1 expression was relatively smaller (∼ 2-fold). Therefore, characteristic changes 
in endogenous BMP activity can not be completely explained by the regulatory 
expression of Gremlin1. BMPs in FBS may also be responsible for induction of 
phosphorylated Smad1/5/8; BMP-2 is relatively heat-stable, and heat-inactivation of 
FBS for 30 min at 56°C would not decrease the bioactivity of BMP-2 [Ohta et al., 
2005]. 
 
Gene transcript levels of TGF-β2 and TGF-β3 were increased after differentiation 
stimulation (Fig. 3B and C). Especially, expression level of TGF-β2 on day 16 was 
∼5-fold higher than that on day -2, implying the role as an inducer of phosphorylation of 
Smad2 during the late phase of myogenesis. Myostatin, also known as GDF-8, is a 
strong inhibitor of myogenesis in skeletal muscle, and transmits its signal through type I 
receptor for activin (ALK4) or TGF-β (ALK5) and subsequently via Smad2 
[Rebbapragada et al., 2003]; however, no significant expression of Myostatin was 
detected (Fig. 3D). In addition, Smad2 phosphorylation was detected in response to 
exogenously administered TGF-β1 but not activin A (Fig. 3E, lanes 1–3). Thus, Smad2 
activity in C2C12 cells reflects endogenous TGF-β activity but not Myostatin and 
activin activities. 
 
PROPER BMP ACTIVITY BEFORE DIFFERENTIATION IS REQUIRED FOR 
DIFFERENTIATION OF C2C12 MYOBLASTS 
Dorsomorphin is an inhibitor of the BMP pathway, which inhibits the activation of BMP 
type I receptors, i.e., ALK2, 3 and 6, but not ALK4 and 5 in several types of cells [Yu et 
al., 2008b; Suenaga et al., 2010]. Treatment with dorsomorphin significantly 
down-regulated the expression of Id1, indicating the effectiveness of this compound 
9 
 
also in C2C12 myoblasts (Fig. 4A). Immunofluorescent analyses revealed that treatment 
with dorsomorphin for 2 days before differentiation stimulation decreased myotube 
formation on day 8 (Fig. 4B). Dorsomorphin treatment in undifferentiated C2C12 cells 
also decreased the expression of MyHC after differentiation stimulation (Fig. 4C, upper), 
which was consistent with MyHC IIb mRNA on day 8 (Fig. 4D). In addition, the 
treatment resulted in a lower expression of Myf5, especially on day 0 (Fig. 4C, middle). 
Comparable results were also detected on gene transcript levels of Myf5 and MyoD on 
day 0 (Fig. 4E). 
 
Dorsomorphin was originally identified as an inhibitor for the AMPK pathway [Yu et al., 
2008b]. Thus, results shown above may reflect effects of inhibition of endogenous 
AMPK activity. However, we could not detect phosphorylation of AMPKα1 at Ser485, 
a site of autophosphorylation [Hurley et al., 2006] (data not shown), suggesting that 
endogenous AMPK activity was lower. LDN-193189 is another inhibitor of BMP type I 
receptor, which is more selective and potent than dorsomorphin [Yu et al., 2008a]. 
Treatment with LDN-193189 for 2 days before differentiation stimulation caused 
down-regulation of Id1, Myf5 and MyoD expression on day 0 (Fig. 5A-C), and MyHC 
IIb expression on day 8 (Fig. 5D). We further examined effects of pretreatment with 
noggin, a BMP antagonist [Yanagita, 2005], for 2 days before differentiation stimulation. 
Comparable results on expression of Id1, Myf5, MyoD and MyHC IIb were obtained 
(Fig. 5E-H). These results suggest that blocking BMP activity prior to differentiation 
stimulation impairs myotube formation, probably through down-regulation of MRF 
expression. 
 
To test whether higher BMP activity in undifferentiated C2C12 cells enhances 
myogenic differentiation, BMP-2 was added to growth medium for 2 days before 
differentiation stimulation (Fig. 6); however, exogenous BMP-2 decreased myotube 
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formation on 8 days after differentiation stimulation in a dose-dependent manner (Fig. 
6A). Expression of MyHC on day 8 was also decreased by BMP-2 addition both at the 
protein level (Fig. 6B) and at the mRNA level (Fig. 6C). Furthermore, treatment with 
BMP-2 down-regulated the expression of MyoD (Fig. 6B and D) and Myf5 (Fig. 6D). 
Experiments using the inhibitor and ligand suggest that the appropriate level of BMP 
activity in undifferentiated proliferating myoblasts is necessary for efficient 
differentiation into myotubes. 
 
ENDOGENOUS TGF-β ACTIVITY AFTER DIFFERENTIATION INHIBITS 
EXCESS MYOTUBE FORMATION IN C2C12 CELLS 
We next examined the role of endogenous TGF-β activity during the period after 
differentiation. A-83-01 is an inhibitor of ALK4 and ALK5 [Tojo et al., 2005]; as 
expected, the inhibitor blocked TGF-β1-induced Smad2 phosphorylation in C2C12 cells 
(Fig. 3E, lanes 2 and 6). A-83-01 also blocked TGF-β-induced Smad1/5/8 
phosphorylation. Comparable results were also shown in a previous study [Wrighton et 
al., 2009]; pre-treatment with SB431542, another inhibitor of ALK5 [Inman et al., 
2002], eliminated TGF-β-induced Smad1 phosphorylation in C2C12 cells. Treatment 
with A-83-01 from day 8 to 12 increased myotube formation (Fig. 7A), and the 
expression of MyHC (Fig. 7B). The treatment also increased the expression of Myf5 and 
MyoD (Fig. 7C). Culture under low-mitogen conditions does not differentiate all 
myoblasts into myotubes, and there are residual myoblasts after differentiation 
stimulation [Kitzmann et al., 1998; Menconi et al., 2008, Umemoto et al., unpublished 
data]. Mononucleated cells are classified into two types of cells on MyoD and Myf5; 
differentiated (MyoD-positive) and reserve (MyoD-negative) cells, which are 
undifferentiated but retain their myogenic potential [Yoshida et al., 1998]. Thus, these 
results suggest that the removal of endogenous TGF-β activity activates reserve cells, 
leading to differentiated myoblasts capable of differentiation into myotubes. 
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 To examine whether inhibitory effect of endogenous TGF-β activity on myogenesis is 
limited to post-differentiation, A-83-01 was treated at various differentiation stages (Fig. 
8A). Treatment with A-83-01 not only after differentiation (stages B-D) but also prior to 
differentiation (stage A) increased MyHC expression on day 12, although the effect of 
A-83-01 was stronger at stages C and D than at stages A and B (Fig. 8B and C). These 
results were consistent with gene transcript levels of MyHC IIb (Fig. 8D). Expression of 
Myf5 and MyoD was also higher in C2C12 cells treated with A-83-01 at stage D (Fig. 





Here we show differentiation-related changes in endogenous activities of the TGF-β 
family in C2C12 myoblasts. Endogenous BMP activity was higher in undifferentiated 
myoblasts, which was indispensable for myotube differentiation. Similar activity of 
BMP is shown during adipocyte differentiation; endogenous BMP activity in 3T3-L1 
preadipocytes was higher before differentiation stimulation, and this activity is 
necessary for the preadipocytic property [Suenaga et al., 2010]. By contrast, TGF-β 
activity was relatively lower during the undifferentiated myoblast phase, and gradually 
increased after differentiation. Endogenous TGF-β activity negatively regulated 
myotube formation. The present results indicate that two representative TGF-β family 
members, i.e., TGF-β and BMP, endogenously control myogenesis in a stage-specific 
manner. 
 
Previous studies revealed that the addition of BMP to low-mitogen differentiation 
medium inhibited myotube differentiation, and promoted osteoblast differentiation 
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[Katagiri et al., 1994; Lee et al., 2000; Maeda et al., 2004]. BMP-induced expression of 
Id1 is suggested to mediate the inhibition of myogenesis [Katagiri et al., 1994; Vinals 
and Ventura, 2004]. Id1 heterodimerizes with E proteins, which interferes with the 
formation of the active complex of E proteins and MyoD. Thus, the Id1 and E protein 
complex inhibits the function MyoD to function as a transcription factor [Benezra et al., 
1990; Sun et al., 1991]. In addition, Id1 expression also accelerated the degradation of 
myogenin [Vinals and Ventura, 2004]. In the present study, myogenesis was also 
inhibited by the short-term addition of BMP-2 to growth medium but not to 
differentiation medium. MRFs are possibly modulated as described above, since 
exogenous BMP-2 induced Id1 expression in C2C12 undifferentiated myoblasts (Fig. 
3A). The treatment also down-regulated the expression of Myf5 and MyoD (Fig. 4B and 
C). Since Myf5 and MyoD regulate the early events of myogenesis [Ludolph and 
Konieczny, 1995; Perry and Rudnick, 2000; Lluis et al., 2006], down-regulation of 
Myf5 and MyoD expression may be critical for the inhibition of myotube formation by 
exogenous BMP. 
 
Decreased endogenous BMP activity by inhibitors for the BMP pathways before 
differentiation also inhibited myotube formation. Because the inhibitors potentiated the 
down-regulation of Myf5 and MyoD expression, the impaired action of MRFs in relation 
to the expression level may be responsible for suppressed myotube differentiation. It 
should be evaluated whether decreased endogenous BMP activity after differentiation 
inhibits myogenesis in future studies. Considering that Smads act as transcriptional 
regulators [Feng and Derynck, 2005; Massagué et al., 2005; Heldin, 2008], basal BMP 
activity may regulate expression of MRFs through Smad-dependent signaling. In 
contrast to the effects of exogenous BMP-2, the involvement of Id1 in the modulation of 
differentiation is unlikely, since the treatment with the inhibitors decreased the 
expression of Id1. 
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 Optimal BMP activity before differentiation was therefore indispensable for myotube 
differentiation; both the increase and decrease in BMP activity resulted in impaired 
myotube formation. Molecular bases of the dual effects of BMP activity are currently 
unclear. Undifferentiated myoblasts possibly sense BMP concentrations and 
differentiate within the limited levels of BMP. The concentration-dependent effects of 
the TGF-β family have been well established; dpp, a Drosophila BMP molecule, acts as 
a morphogen during embryogenesis [Affolter and Basler, 2007]. Alternatively, a 
difference in the mode of changing BMP activity may affect the results; BMP activity 
was increased by adding BMP-2 to the culture medium, whereas it was decreased by 
treatment with the inhibitors for type I receptors for BMP, ALK2, 3 and 6 [Yu et al., 
2008a, b; Suenaga et al., 2010]. As mentioned above, type II receptor acts as an 
activator of type I receptor in the current signaling model [Feng and Derynck, 2005; 
Massagué et al., 2005; Heldin, 2008]. However, BMP type II receptor has a long 
C-terminal tail with 530 amino acids after the kinase domain, where some effector 
molecules are bound to modulate the BMP signal through the non-Smad pathway in a 
type I receptor-independent manner [Miyazono et al., 2010]. 
 
Treatment with A-83-01 in C2C12 cells intrinsically enhanced myotube formation in a 
stage-independent manner, suggesting that endogenous TGF-β potentially inhibits 
myogenesis. This is basically consistent with the results by Maeda et al. [2004] using 
SB431542; SB431542 accelerated myotube formation of C2C12 cells, irrespective of 
serum concentration in culture medium. The enhanced myotube formation was 
especially evident by the treatment with A-83-01 in a late phase of myogenesis, which 
corresponded to the period of higher endogenous TGF-β activity. Consistent with the 
notion of the present results, exogenous TGF-β inhibited myotube formation in C2C12 
cells under low-mitogen conditions [Olson et al., 1986]. However, TGF-β promoted 
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myoblast differentiation under high-mitogen conditions in L6E9 myoblasts [Zentella 
and Massagué, 1992], and stimulated the myogenic differentiation of uncommitted 
embryonic stem cells [Slager et al., 1993]. Culture conditions and cell differentiation 
stages possibly affect TGF-β effects. Furthermore, the expression of dominant-negative 
type II TGF-β receptor (TβRII), which lacks most of the cytoplasmic domain, including 
the kinase domain, delayed the differentiation of C2C12 myoblasts in low-mitogen 
differentiation medium [Filvaroff et al., 1994]. TβRII serine/threonine kinase also 
phosphorylated Par6, a regulator of cell polarity and tight-junction assembly, in a 
ligand-dependent manner [Ozdamar et al., 2005]. Thus, the kinase activity of TβRII 
beyond the phosphorylation of ALK5 may explain the discrepant results. 
 
Other pathways including MAP kinase pathway, mTOR pathway and Hippo pathway 
regulate various stages of myoblast differentiation [Bennett and Tonks, 1997; Erbay and 
Chen, 2001; Park and Chen, 2005; Watt et al., 2010]. Since these pathways also affect 
TGF-β/BMP pathway [Feng and Derynck, 2005; Alarcón et al., 2009; Miyazono et al., 
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Fig. 1. Time-course changes in Smad phosphorylation and Smad expression 
during myotube differentiation in C2C12 myoblasts 
C2C12 myoblasts were cultured to confluence (day 0) in growth medium, followed by 
culture in differentiation medium. (A) Equal amount of protein was subjected to 
Western blot analyses to detect expressions of phosphorylated and total Smad, and 
β-actin. A representative result is shown. (B and C) The band intensity of total and 
phosphorylated Smad2 and Smad8, and β-actin was quantified. The levels of 
phosphorylated Smad8 (B) and Smad2 (C) were plotted against days pre- or 
post-differentiation. Gene transcript levels of Smad1 (D), 5 (E) and 8 (F) or Smad2 (G) 
and 3 (H) were quantified by qRT-PCR. Smad expression was normalized to Hprt1 
expression, and the expression on day -2 was set to 1. Data are shown as the mean ± SE 
(n = 3). 
 
 
Fig. 2. Time-course changes in Ids expression during myotube differentiation in 
C2C12 myoblasts 
C2C12 myoblasts were cultured to confluence (day 0) in growth medium, followed by 
culture in differentiation medium. Gene transcript levels of Id1 (A), Id2 (B) and Id3 (C) 
were quantified by qRT-PCR. Expression of Ids was normalized to Hprt1 expression, 
and the expression on day -2 was set to 1. Data are shown as the mean ± SE (n = 3) 
 
 
Fig. 3. Time-course changes in Gremlin1, TGF-β2, TGF-β3 and Myostatin 
expression during myotube differentiation in C2C12 myoblasts and Smad 
phosphorylation in response to TGF-β family ligand 
C2C12 myoblasts were cultured to confluence (day 0) in growth medium, followed by 
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culture in differentiation medium. Gene transcript levels of Gremlin1 (A), TGF-β2 (B) 
and TGF-β3 (C) were quantified by qRT-PCR. Expression of the genes was normalized 
to Hprt1 expression, and the expression on day -2 was set to 1. Data are shown as the 
mean ± SE (n = 3). (D) Time-course changes in Myostatin expression were examined by 
RT-PCR. A representative result is shown. (E) C2C12 cells were treated with or without 
A-83-01 (4 µM) for 15 min, followed by treatment with TGF-β1 (200 pM), activin A (4 
nM) or BMP-2 (4 nM) for 1 h. Phosphorylated Smad1/5/8 and Smad2 were examined 
by Western blot analyses. A representative result is shown. 
 
 
Fig. 4. Myotube differentiation in C2C12 myoblasts treated with dorsomorphin 
before differentiation 
C2C12 myoblasts were cultured in growth medium with or without dorsomorphin (4 
µM) or BMP-2 (4 nM) for 2 days prior to reaching confluence (day -2 to 0), followed 
by culture in differentiation medium. (A and E) Gene transcript levels of Id1 (A), Myf5 
and MyoD (E) on day 0 were quantified by qRT-PCR in C2C12 myoblasts for 2 days 
before differentiation. The expression was normalized to Hprt1 expression, and the 
expression in cells treated without the inhibitor or ligand was set to 1 (n = 2-3). (B) On 
day 8, myotube formation was examined by immunofluorescent analyses using 
anti-MyHC antibody. Fusion index was calculated as the ratio of nuclei incorporated 
into myotubes relative to total nuclei, and the index of cells treated without 
dorsomorphin was set to 1 (n = 3). (C) Time-course changes in expressions of MyHC, 
Myf5 and β-actin were examined during myotube differentiation in C2C12 myoblasts 
treated with or without dorsomorphin (4 µM) for 2 days prior to differentiation. (D) 
Gene transcript levels of MyHC IIb on day 8 were quantified by qRT-PCR in C2C12 
myoblasts treated with or without dorsomorphin (4 µM) for 2 days before 
differentiation. The expression was normalized to Hprt1 expression, and the expression 
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in cells treated without the inhibitor was set to 1 (n = 3). 
 
 
Fig. 5. Response to treatment with LDN-193189 or noggin before differentiation 
in C2C12 cells 
C2C12 myoblasts were cultured in growth medium with or without LDN-193189 (- and 
+: 0 and 100 nM, respectively) (A-D) or noggin (-, +, and ++: 0, 2.5, and 25 ng/ml, 
respectively) (E-H) for 2 days prior to reaching confluence (day -2 to 0), followed by 
culture in differentiation medium. Gene transcript levels of Id1 (A and E), Myf5 (B and 
F), and MyoD (C and G) on day 0, and MyHC IIb (D and H) on day 8were quantified by 
qRT-PCR. The expression was normalized to Hprt1 expression, and the expression in 
cells treated without the inhibitor was set to 1 (n = 3). 
 
 
Fig. 6. Myotube differentiation in C2C12 myoblasts treated with BMP-2 before 
differentiation 
(A) C2C12 myoblasts were cultured in growth medium with or without BMP-2 (-, +, 
and ++: 0, 0.8, and 4 nM, respectively) for 2 days prior to reaching confluence (day -2 
to 0), followed by culture in differentiation medium. On day 8, myotube formation was 
examined by immunofluorescent analyses using anti-MyHC antibody. Fusion index was 
calculated as the ratio of nuclei incorporated into myotubes relative to total nuclei, and 
the index of cells treated without BMP-2 was set to 1 (n = 3). (B-D) Cells were treated 
with or without BMP-2 at 4 nM from day -2 to day 0, followed by culture in 
differentiation medium. (B) Time-course changes in expressions of MyHC, MyoD and 
β-actin were examined. (C and D) Gene transcript levels of MyHC IIb on day 8 (C) and 
Myf5 and MyoD on day 0 (D) were quantified by qRT-PCR. The expression was 
normalized to Hprt1 expression, and the expression in cells treated without BMP-2 was 
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set to 1 (n = 3). 
 
 
Fig. 7. Myotube differentiation in C2C12 myoblasts treated with A-83-01 during 
differentiation 
(A) C2C12 cells were cultured in differentiation medium with or without A-83-01 (4 
µM) for 4 days (day 8 to 12). On day 12, myotube formation was examined by 
immunofluorescent analyses using anti-MyHC antibody. Fusion index was calculated as 
the ratio of nuclei incorporated into myotubes relative to total nuclei, and the index of 
cells treated without A-83-01 was set to 1 (n = 3). (B) Expression of MyHC and β-actin 
were examined in C2C12 cells treated with or without A-83-01 at the indicated 
concentration for 4 days (day 8–12). (C) Gene transcript levels of Myf5 and MyoD were 
quantified on day 12 by qRT-PCR in C2C12 cells treated with or without A-83-01 (4 
µM) for 4 days (day 8-12). The expression was normalized to Hprt1 expression, and the 
expression in cells without treated with A-83-01 was set to 1 (n = 3). 
 
Fig. 8. Effects of treatment with A-83-01 for various period on myotube 
differentiation 
(A) C2C12 cells were cultured in growth medium (stage A) or differentiation medium 
(stages B-D) with or without A-83-01 (4 µM) for the indicated period. (B) On day 12, 
expression of MyHC and β-actin was examined by Western blot analyses. (C) The band 
intensity of MyHC and β-actin was quantified. The level of MyHC was normalized to 
that of β-actin, and the expression in cells without treated with A-83-01 at stage A was 
set to 100. (D and E) Gene transcript levels of MyHC IIb (D), and Myf5 and MyoD (E) 
were quantified on day 12 by qRT-PCR in C2C12 cells treated with or without A-83-01 
(4 µM). The expression was normalized to Hprt1 expression, and the expression in cells 
without treated with A-83-01 at each stage was set to 1 (n = 3). 
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